Literature DB >> 19880162

Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Wilmer L Sibbitt1, William M Brooks, Mario Kornfeld, Blaine L Hart, Arthur D Bankhurst, Carlos A Roldan.   

Abstract

OBJECTIVE: Magnetic resonance imaging (MRI) often demonstrates brain lesions in neuropsychiatric systemic lupus erythematosus (NPSLE). The present study compared postmortem histopathology with premortem MRI in NPSLE.
METHODS: Two hundred subjects with NPSLE were studied prospectively with MRI over a 10-year period during which 22 subjects died. In 14 subjects, a brain autopsy with histopathology, that permitted direct comparison with premortem MRI, was successfully obtained. Surface anatomy was used to determine the approximate location of individual lesions.
RESULTS: Premortem MRI findings in fatal NPSLE were small focal white matter lesions (100%), cortical atrophy (64%), ventricular dilation (57%), cerebral edema (50%), diffuse white matter abnormalities (43%), focal atrophy (36%), cerebral infarction (29%), acute leukoencephalopathy (25%), intracranial hemorrhage (21%), and calcifications (7%). Microscopic findings in fatal NPSLE included global ischemic changes (57%), parenchymal edema (50%), microhemorrhages (43%), glial hyperplasia (43%), diffuse neuronal/axonal loss (36%), resolved cerebral infarction (33%), microthomboemboli (29%), blood vessel remodeling (29%), acute cerebral infarction (14%), acute macrohemorrhages (14%), and resolved intracranial hemorrhages (7%). Cortical atrophy and ventricular dilation seen by MRI accurately predicted brain mass at autopsy (r = -0.72, P = 0.01, and r = -0.77, P = 0.01, respectively). Cerebral autopsy findings, including infarction, cerebral edema, intracranial hemorrhage, calcifications, cysts, and focal atrophy, were also predicted accurately by premortem MRI.
CONCLUSION: Brain lesions in NPSLE detected by MRI accurately represent serious underlying cerebrovascular and parenchymal brain injury on pathology. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19880162      PMCID: PMC3586567          DOI: 10.1016/j.semarthrit.2009.08.005

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  68 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 2.  Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium.

Authors:  H M Belmont; S B Abramson; J T Lie
Journal:  Arthritis Rheum       Date:  1996-01

3.  Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus.

Authors:  W M Brooks; A Sabet; W L Sibbitt; P B Barker; P C van Zijl; J H Duyn; C T Moonen
Journal:  J Rheumatol       Date:  1997-12       Impact factor: 4.666

4.  Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy.

Authors:  W L Sibbitt; L J Haseler; R R Griffey; S D Friedman; W M Brooks
Journal:  AJNR Am J Neuroradiol       Date:  1997-08       Impact factor: 3.825

5.  Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody.

Authors:  O Ishikawa; K Ohnishi; Y Miyachi; H Ishizaka
Journal:  J Rheumatol       Date:  1994-01       Impact factor: 4.666

6.  Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy.

Authors:  W L Sibbitt; L J Haseler; R H Griffey; B L Hart; R R Sibbitt; N A Matwiyoff
Journal:  AJNR Am J Neuroradiol       Date:  1994-05       Impact factor: 3.825

7.  Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus.

Authors:  M J Jarek; S G West; M R Baker; K M Rak
Journal:  Arthritis Rheum       Date:  1994-11

Review 8.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

9.  Spin-spin relaxation of brain tissues in systemic lupus erythematosus. A method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus.

Authors:  W L Sibbitt; W M Brooks; L J Haseler; R H Griffey; L M Frank; B L Hart; R R Sibbitt
Journal:  Arthritis Rheum       Date:  1995-06

Review 10.  Controversies in lupus: nervous system involvement.

Authors:  G A Bruyn
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

View more
  45 in total

1.  Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.

Authors:  B Namjou; P H Kothari; J A Kelly; S B Glenn; J O Ojwang; A Adler; M E Alarcón-Riquelme; C J Gallant; S A Boackle; L A Criswell; R P Kimberly; E Brown; J Edberg; A M Stevens; C O Jacob; B P Tsao; G S Gilkeson; D L Kamen; J T Merrill; M Petri; R R Goldman; L M Vila; J-M Anaya; T B Niewold; J Martin; B A Pons-Estel; J M Sabio; J L Callejas; T J Vyse; S-C Bae; F W Perrino; B I Freedman; R H Scofield; K L Moser; P M Gaffney; J A James; C D Langefeld; K M Kaufman; J B Harley; J P Atkinson
Journal:  Genes Immun       Date:  2011-01-27       Impact factor: 2.676

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Reduced Insular Glutamine and N-acetylaspartate in systemic lupus erythematosus: a single-voxel (1)H-MR spectroscopy study.

Authors:  Patricia Cagnoli; Richard E Harris; Dan Frechtling; George Berkis; Richard H Gracley; Courtney C Graft; Suzan E Lowe; Thomas L Chenevert; William J McCune; Stephen Gebarski; Pia C Sundgren
Journal:  Acad Radiol       Date:  2013-10       Impact factor: 3.173

4.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

Review 5.  Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches.

Authors:  Aida Zarfeshani; Kaitlin R Carroll; Bruce T Volpe; Betty Diamond
Journal:  Curr Rheumatol Rep       Date:  2021-03-29       Impact factor: 4.592

6.  Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus.

Authors:  Derrick Soh; Anthony Lang
Journal:  Mov Disord Clin Pract       Date:  2019-04-19

7.  White-matter integrity in patients with systemic lupus erythematosus and memory deficits.

Authors:  Diogo G Corrêa; Nicolle Zimmermann; Rafael S Borges; Denis B Pereira; Thomas M Doring; Gustavo Tukamoto; Rochele P Fonseca; Emerson L Gasparetto
Journal:  Neuroradiol J       Date:  2018-08-09

8.  Correlation of neurocognitive function and brain lesion load on magnetic resonance imaging in systemic lupus erythematosus.

Authors:  Paola C Roldan; Rex E Jung; Wilmer L Sibbitt; Clifford R Qualls; Ranee A Flores; Carlos A Roldan
Journal:  Rheumatol Int       Date:  2018-06-13       Impact factor: 2.631

9.  Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.

Authors:  Mari Miyata; Shingo Kakeda; Kohsuke Kudo; Shigeru Iwata; Yoshiya Tanaka; Yi Wang; Yukunori Korogi
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-16       Impact factor: 6.200

10.  Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus.

Authors:  Rex E Jung; Judith M Segall; Rachael G Grazioplene; Clifford Qualls; Wilmer L Sibbitt; Carlos A Roldan
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.